Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with ¹³¹I-MIP-1095.

ABSTRACT:

Purpose

Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies.

Methods

Thirty-four men with metastatic castration-resistant prostate cancer received PSMA-RLT with ¹³¹I-MIP-1095. Twenty-three patients received a second, and three patients a third dose, timed at PSA progression after an initial response to the preceding therapy. The applied doses were separated in three groups: <3.5, 3.5-5.0 and >5.0 GBq. Antitumor and side-effects were analyzed by blood samples and other clinical data. Follow-up was conducted for up to 5 years.

Res

SUBMITTER: Afshar-Oromieh A 

PROVIDER: S-EPMC5397661 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature